These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9649675)

  • 1. Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata.
    Nasca MR; Micali G; Pulvirenti N; Licastro Cicero R
    Eur J Dermatol; 1998 Mar; 8(2):125-6. PubMed ID: 9649675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata].
    Valsecchi R; Pansera B; Rossi A; Cainelli T
    G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical immunotherapy of alopecia areata. A follow-up study.
    Valsecchi R; Cainelli T; Foiadelli L; Rossi A
    Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of alopecia areata with squaric acid dibutylester.
    Caserio RJ
    Arch Dermatol; 1987 Aug; 123(8):1036-41. PubMed ID: 3307636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata.
    Guerra L; Pacifico V; Calabresi V; De Luca N; Castiglia D; Angelo C; Zambruno G; Di Zenzo G
    Br J Dermatol; 2017 Feb; 176(2):491-494. PubMed ID: 27208509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Squaric acid dibutyl ester in the treatment of severe alopecia areata].
    Miranda A; Mato F; Quiñones PA
    Med Cutan Ibero Lat Am; 1984; 12(3):273-8. PubMed ID: 6384701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
    Aghaei S
    BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of alopecia areata with squaric acid dibutylester.
    Hill ND; Bunata K; Hebert AA
    Clin Dermatol; 2015; 33(3):300-4. PubMed ID: 25889130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases.
    Inui S; Nakajima T; Toda N; Itami S
    J Dermatol; 2009 Jun; 36(6):323-7. PubMed ID: 19500180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the sildenafil effect on alopecia areata in childhood: An open-pilot comparison study.
    Sarifakioglu E; Degim IT; Gorpelioglu C
    J Dermatolog Treat; 2006; 17(4):235-7. PubMed ID: 16971319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH; Goh CL; Ang CB
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
    Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
    Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squaric acid dibutylester: indications for use and efficacy in alopecia areata.
    Pardasani AG; Turner E; McMichael AJ
    Arch Dermatol; 2001 Jul; 137(7):970-2. PubMed ID: 11453831
    [No Abstract]   [Full Text] [Related]  

  • 19. [DNCB therapy of alopecia areata].
    Happle R
    Z Hautkr; 1979 May; 54(10):426-9. PubMed ID: 314203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
    Mastrolonardo M; Diaferio A
    J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.